Beam Therapeutics Shares Climb After Updates to Treatment-Candidate Pipelines

Dow Jones01-13

By Elias Schisgall

Beam Therapeutics shares climbed after the company said it plans to file an application for its risto-cel treatment and had reached alignment with the Food and Drug Administration on potential accelerated approval for another treatment.

Shares rose 28% to $35.37 midday Monday. The stock has gained 34% in the past year.

The genetic-disease medicine company said late Sunday that it expects to file a biologics licensing application for risto-cel, a treatment for glycogen storage disease type Ia previously known as BEAM-301, as early as the end of 2026.

The company also said it had reached alignment with the FDA on an accelerated approval pathway for BEAM-302, a therapy for alpha-1 antitrypsin deficiency. It said approval depended on alpha-1 antitrypsin biomarkers over the next 12 months, adding that it was expanding its ongoing Phase 1/2 study of the drug.

Beam said it expects to report updated data from that trial by the end of the first quarter, adding that both drug candidates have been accepted into the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot program.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 12, 2026 12:05 ET (17:05 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603542709?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 01:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603542709","market":"nz","top_or_hot":-1,"title":"Beam Therapeutics Shares Climb After Updates to Treatment-Candidate Pipelines","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares climbed after the company said it plans to file an application for its risto-cel treatment and had reached alignment with the Food and Drug Administration on potential accelerated approval for another treatment. \n</p>\n<p>\n  Shares rose 28% to $35.37 midday Monday. The stock has gained 34% in the past year. \n</p>\n<p>\n  The genetic-disease medicine company said late Sunday that it expects to file a biologics licensing application for risto-cel, a treatment for glycogen storage disease type Ia previously known as BEAM-301, as early as the end of 2026. \n</p>\n<p>\n  The company also said it had reached alignment with the FDA on an accelerated approval pathway for BEAM-302, a therapy for alpha-1 antitrypsin deficiency. It said approval depended on alpha-1 antitrypsin biomarkers over the next 12 months, adding that it was expanding its ongoing Phase 1/2 study of the drug. \n</p>\n<p>\n  Beam said it expects to report updated data from that trial by the end of the first quarter, adding that both drug candidates have been accepted into the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot program. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 12:05 ET (17:05 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics Shares Climb After Updates to Treatment-Candidate Pipelines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics Shares Climb After Updates to Treatment-Candidate Pipelines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-13 01:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares climbed after the company said it plans to file an application for its risto-cel treatment and had reached alignment with the Food and Drug Administration on potential accelerated approval for another treatment. \n</p>\n<p>\n  Shares rose 28% to $35.37 midday Monday. The stock has gained 34% in the past year. \n</p>\n<p>\n  The genetic-disease medicine company said late Sunday that it expects to file a biologics licensing application for risto-cel, a treatment for glycogen storage disease type Ia previously known as BEAM-301, as early as the end of 2026. \n</p>\n<p>\n  The company also said it had reached alignment with the FDA on an accelerated approval pathway for BEAM-302, a therapy for alpha-1 antitrypsin deficiency. It said approval depended on alpha-1 antitrypsin biomarkers over the next 12 months, adding that it was expanding its ongoing Phase 1/2 study of the drug. \n</p>\n<p>\n  Beam said it expects to report updated data from that trial by the end of the first quarter, adding that both drug candidates have been accepted into the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot program. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 12:05 ET (17:05 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603542709","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603542709","pubTimestamp":1768237500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Beam Therapeutics shares climbed after the company said it plans to file an application for its risto-cel treatment and had reached alignment with the Food and Drug Administration on potential accelerated approval for another treatment.Shares rose 28% to $35.37 midday Monday. The stock has gained 34% in the past year.The genetic-disease medicine company said late Sunday that it expects to file a biologics licensing application for risto-cel, a treatment for glycogen storage disease type Ia previously known as BEAM-301, as early as the end of 2026.The company also said it had reached alignment with the FDA on an accelerated approval pathway for BEAM-302, a therapy for alpha-1 antitrypsin deficiency. It said approval depended on alpha-1 antitrypsin biomarkers over the next 12 months, adding that it was expanding its ongoing Phase 1/2 study of the drug.Beam said it expects to report updated data from that trial by the end of the first quarter, adding that both drug candidates have been ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4588":"碎股","BK4539":"次新股","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4611":"AI医疗","BEAM":"Beam Therapeutics, Inc.","BK4007":"制药"},"translate_title":"Beam Therapeutics股价在候选治疗管道更新后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"BEAM":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Beam Therapeutics shares climbed after the company said it plans to file an application for its risto-cel treatment and had reached alignment with the Food and Drug Administration on potential accelerated approval for another treatment. \n\n\n  Shares rose 28% to $35.37 midday Monday. The stock has gained 34% in the past year. \n\n\n  The genetic-disease medicine company said late Sunday that it expects to file a biologics licensing application for risto-cel, a treatment for glycogen storage disease type Ia previously known as BEAM-301, as early as the end of 2026. \n\n\n  The company also said it had reached alignment with the FDA on an accelerated approval pathway for BEAM-302, a therapy for alpha-1 antitrypsin deficiency. It said approval depended on alpha-1 antitrypsin biomarkers over the next 12 months, adding that it was expanding its ongoing Phase 1/2 study of the drug. \n\n\n  Beam said it expects to report updated data from that trial by the end of the first quarter, adding that both drug candidates have been accepted into the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot program. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 12:05 ET (17:05 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603542709","isCrawlerRequest":true}